| Name | Title | Contact Details |
|---|
Prosthodent Dental Studio is a Clinton Township, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cedar Court Imaging is a Carbondale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kinetics West Inc is a Littleton, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brookhaven National Laboratory delivers discovery science and transformative technology to power and secure the nation`s future. Primarily supported by the U.S. Department of Energy`s (DOE) Office of Science, Brookhaven is a multidisciplinary laboratory with seven Nobel Prize-winning discoveries, 36 R&D 100 Awards, and more than 70 years of pioneering research. Our 2,500-plus staff members lead and support diverse research teams that address the DOE mission to ensure the nation`s security and prosperity by addressing its energy, environmental, and nuclear challenges through transformative science and technology solutions. Brookhaven`s highest-level priorities are nuclear science, energy science, data science, particle physics, accelerator science & technology, quantitative plant science, and quantum information science.
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.